Bacteraemia - Pipeline Insight, 2024

This “Bacteraemia - pipeline insight 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Bacteraemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bacteraemia Understanding

Bacteraemia: Overview

Bacteremia refers to the presence of live bacteria in the bloodstream. It can develop asymptomatically during routine activities such as brushing one's teeth or following minor medical treatments. Release of bacterial toxins into the bloodstream, can trigger a strong immunological response, resulting in systemic inflammatory response syndrome. Another term which can be used for Bacteraemia is “Blood Poisoning”. There are many different bacterias which can cause bacteraemia: Staphylococcus aureus, including MRSA, Escherichia coli (E. coli), Pneumococcal bacteria, Group A Streptococcus, Salmonella species, Pseudomonas aeruginosa. Symptoms can include: fever, chills, shaking or shivering. Diagnosis can be done by using blood culture, Imaging tests such as an X-ray, CT scan, or ultrasound may also be used. Antibiotics can be used of the treatment purpose.

Bacteraemia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bacteraemia pipeline landscape is provided which includes the disease overview and Bacteraemia treatment guidelines. The assessment part of the report embraces, in depth Bacteraemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bacteraemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Bacteraemia R&D. The therapies under development are focused on novel approaches to treat/improve Bacteraemia.
• In July 2021 Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera (ceftobiprole) covering Russia and the Eurasian Economic Union.
• In February 2020 ContraFect Announces US FDA Granted Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
• In October 2021 Zai lab and Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase III ATTACK trial.

Bacteraemia Emerging Drugs Chapters

This segment of the Bacteraemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bacteraemia Emerging Drugs

Ceftobiprole medocaril : Basilea PharmaceuticaCeftobiprole medocaril is the water-soluble prodrug of the pyrrolidinone cephalosporin, ceftobiprole. It is developed for IV administration. It exhibits extensive antibacterial action against Gram-positive and Gram-negative bacteria, including methicillin-resistant staphylococci, penicillin-resistant pneumococci, and Enterococcus faecalis. A unique combination of properties in ceftobiprole medocaril inhibits all transpeptidases, including the penicillin-binding protein (PBP) 2a. It is designed specifically to bind to this penicillin-resistant target. In January 2022 Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections. A phase 3 Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis.

Exebacase : ContraFectExebacase (CF301) is a lysine with potent activity against Staphylococcus aureus. It has the potential to become a new first-line treatment for patients with staphylococcal bacteremia. It targets a highly conserved region of the cell wall, which is important for bacteria, making it less likely that resistance will develop. When used in combination with SOC antibiotics, the result is a new therapeutic modality capable of addressing the high unmet clinical need for Staph aureus infections. It was the first and only lysine to enter a human clinical trial in the United States. Adding exebacase to vancomycin or daptomycin significantly increased survival in animal models of the disease compared with treatment with SOC antibiotics or exebacase alone. A Phase III Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis.

Bacteraemia: Therapeutic Assessment

This segment of the report provides insights about the different Bacteraemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bacteraemia

There are approx. 7+ key companies which are developing the therapies for Bacteraemia. The companies which have their Bacteraemia drug candidates in the most advanced stage, i.e. phase III include, Basilea Pharmaceutica.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Bacteraemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bacteraemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bacteraemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bacteraemia drugs.

Bacteraemia Report Insights

• Bacteraemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bacteraemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bacteraemia drugs?
• How many Bacteraemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bacteraemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bacteraemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bacteraemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• XBiotech
• LegoChem Biosciences
• Basilea Pharmaceutica
• ContraFect
• Merck & Co.
• Cumberland Pharmaceuticals
• Theravance Biopharma
• Entasis Therapeutics
• Melinta Therapeutics
• GlaxoSmithKline

Key Products

• Omodenbamab
• Delpazolid
• Ceftobiprole medocaril
• Exebacase
• Daptomycin intravenous
• Telavancin
• Tedizolid
• Durlobactam/sulbactam
• Meropenem/vaborbactam
• Pneumococcal vaccine conjugate 10-valent

This product will be delivered within 1-3 business days.